Skip to content
The Uromigos cover art

All episodes

The Uromigos, 501 episodes. Page 4 of 6.

#
Title
301

Episode 243: ASCO 2023 TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide

302

Episode 242: ASCO 2023 THOR study - erdafitinib vs chemo in bladder cancer

303

Episode 241: Statistics for clinical trials

304

Episode 240: Preview of GU Cancer at ASCO 2023

305

Episode 239: The STAMPEDE trial

306

Episode 238: Paper of the month: Biomarkers for neoadjuvant PD(L)1 therapy

307

Episode 237: 2023 AUA Highlights

308

Episode 236: ODAC for olaparib

309

Episode 235: Danny Heng and the IMDC classification in renal cancer

310

Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer

311

Episode 233: Destaques da 14ª reunião internacional brasileira de câncer urológico

312

Episode 232: Belzutifan in early and late renal cancer

313

Episode 231: Ursula Vogl, MD in the Rising Star Series

314

Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand

315

Episode 229: Kala Sridhar, MD on PET in Early Bladder Cancer

316

Episode 228: Karine Tawagi, MD in the Rising Star Series

317

Episode 227: 2023 ASCO GU Bladder Highlights and Paper of the Month with Michiel Van der Heijden

318

Episode 226: 2023 ASCO GU Prostate and RCC Highlights With Dan George

319

Episode 225: ASCO GU 2023: Brian Shuch, MD discusses the ZIRCON Phase III Study of girentuximab PET/CT imaging in RCC

320

Episode 224: ASCO GU 2023: discussing miR371 for Germ Cell Tumors with Christian Kollmannsberger

321

Episode 223: ASCO GU 2023: Discussing KEYNOTE-057 with Andrea Necchi, MD

322

Episode 222: ASCO GU 2023: New Data From IMvigor130 with Enrique Grande, MD

323

Episode 221: ASCO GU 2023: Matt Galsky, MD Gives an Update on the CheckMate 274 Trial

324

Episode 220: ASCO GU 2023: Discussing PARPi for CRPC with Michael Morris, MD

325

Episode 219: ASCO GU 2023: Neeraj Agarwal, MD, FASCO Discusses the TALAPRO-2 study

326

Episode 218: Discussing The Cost of Cancer Drugs With Daniel Goldstein, MD

327

Episode 217: Rising Star: Vadim Koshkin and ADCs

328

Episode 216: ADCs in Bladder Cancer With Petros Grivas, MD, PhD

329

Episode 215: Resumen cáncer de próstata y vejiga reunión Canarias

330

Episode 214: Resumen de la reunión en las Islas Canarias sobre cáncer renal

331

Episode 213: IL-15RaFc superagonist in NMIBC

332

Episode 212: What's coming in GU Cancers in 2023

333

Episode 211: CAR-T cell therapy in RCC

334

Episode 210: Christmas Prostate Cancer Debate - olaparib and abiraterone in selected or unselected patients

335

Episode 209: Christmas Bladder Cancer Debate - Cisplatin vs carboplatin in bladder cancer

336

Episode 208: Christmas Kidney Cancer Debate - Ipilimumab in renal cancer

337

Episode 207: Editorial on COSMIC-313

338

Episode 206: Dan Shapiro in the Rising Star series

339

Episode 205: Paper of the Month - Nab-paclitaxel and pembrolizumab in bladder cancer

340

Episode 204: Scott Haake in the Rising Star series

341

Episode 203: Renee Saliby in the Rising Star series

342

Episode 202: The Uromigos Paper of the Month - Docetaxel with or without continuous enza in CRPC

343

Episode 201: PARPi in CRPC

344

Episode 200: Chromophobe renal cancer

345

Episode 199: The Uromigos Paper of the Month - FGFR inhibition in bladder cancer

346

Episode 198: The RADICALS trial in prostate cancer

347

Episode 197: The Uromigos Nashville 2022

348

Episode 196: The COSMIC-313 Trial cabo/ipi/nivo in 1st line renal cancer

349

Episode 195 ESMO 2022: EV Pembrolizumab in 1st line bladder cancer

350

Episode 194 ESMO 2022: Pegylated il-2 + nivolumab in renal cancer

351

Episode 193 ESMO 2022: PRESTO - a phase III trial of androgen annihilation in biochemically relapsed prostate cancer

352

Episode 192 ESMO 2022: Summary of ESMO Adjuvant RCC Trials

353

Episode 191 ESMO 2022: PROSPER study of neoadjuvant nivolumab in RCC

354

Episode 190: ESMO 2022 Preview

355

Episode 189: The Uromigos Paper of the Month - Robotic vs open cystectomy

356

Episode 188: The 1st Uromigos Live and Unplugged face-to-face meeting

357

Episode 187: Cora Sternberg - The Uromigos Legends Series

358

Episode 186: Bernard Escudier - The Uromigos Legends Series

359

Episode 185: The Uromigos Paper of the Month - ctDNA in prostate cancer

360

Episode 184: Active surveillance in prostate cancer and the seeds of doubt

361

Episode 183: Oliver Sartor - The Uromigos Legends Series

362

Episode 182: ASCO Kidney Cancer Guidelines

363

Episode 181: Relapsed Germ Cell Tumours

364

Episode 180: Enzalutamide vs active surveillance in early prostate cancer

365

Episode 179: PSMA PET for Lutetium-177 in prostate cancer

366

Episode 178: ASCO 2022: Germline variants in men of African descent with prostate cancer

367

Episode 177: ASCO 2022: ENZAMET survival update

368

Episode 176: ASCO 2022: HER-2 ADCs in Bladder Cancer

369

Episode 175: ASCO 2022: Targeting the microbiome in renal cancer

370

Episode 174: ASCO 2022: Cell free DNA as a biomarker in bladder cancer

371

Episode 173: ASCO 2022: The Atlantis Trial - maintenance cabozantinib in bladder cancer

372

Episode 172: ASCO 2022: Adjuvant everolimus in renal cancer

373

Episode 171: Antibody drug conjugates in bladder cancer: managing adverse effects

374

Episode 170: APCCC Meeting Summary

375

Episode 169: The Uromigos Paper of the Month - Novel neoadjuvant approaches in UC

376

Episode 168: Mechanisms of response to PD1 therapy in renal cancer

377

Episode 167: Highlights from EIKCS oral session

378

Episode 166: Prostate cancer debate: doublet vs triplet first line therapy

379

Episode 165: Paper of the Month - ENZAMET quality of life data

380

Episode 164: Paper of the Month - what can we learn from R3 ipilimumab/nivolumab in gastric cancer

381

Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer

382

Episode 162: Debate - Adjuvant nivolumab for bladder cancer

383

Episode 161: Platinum eligibility in urothelial cancer

384

Episode 160: APCCC - PMSA PET as a diagnostic

385

Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer

386

Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer

387

Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer

388

Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer

389

Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC

390

Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer

391

Episode 153: Overview of PARP inhibition in prostate cancer

392

Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging

393

Episode 151: Bladder Cancer ESMO Guidelines update

394

Episode 150: Comparing the quality of life data in renal trials

395

Episode 149: Treatment-free survival for ipilimumab and nivolumab

396

Episode 148: The Uromigos Paper of the Month - Stereotactic radiotherapy for advanced renal cancer

397

Episode 147: Renal Cancer Christmas Special

398

Episode 146: Bladder Cancer Christmas Special

399

Episode 145: Prostate Cancer Christmas Special

400

Episode 144: Pembrolizumab for bladder cancer